Eli Lilly and Company's Net Income Surges 64.44% in Q2 2025

Eli Lilly and Company announced its financial results for the second quarter of 2025, reporting revenue of $9,545.9 million. This represents a 17.79% increase compared to $8,103.7 million in the same period last year. Net income for the quarter stood at $2,168.3 million, marking a significant rise of 64.44% from $1,318.6 million in the prior-year quarter. The company surpassed analyst revenue estimates of $14,668.74 million but fell short of analyst EPS estimates of $5.61, as specific EPS figures were not provided in the filing.

Key Business Drivers

The company's performance was significantly driven by strong sales across its key pharmaceutical products. Notably, sales of Trulicity reached $2,284.1 million for the quarter, up from $2,008.2 million in the prior year. Additionally, sales of Taltz increased to $771.6 million from $718.3 million, and Jardiance sales grew to $758.3 million from $606.3 million. Verzenio contributed $1,274.6 million in sales, a substantial increase from $971.0 million in the previous year, while Mounjaro sales soared to $1,811.3 million from $979.7 million.

Other products also showed robust growth. Olumiant sales rose to $227.0 million from $211.5 million, and Cyramza sales saw a modest increase to $218.4 million from $206.5 million. Basaglar sales were $145.4 million, up from $127.1 million. However, Alimta sales declined to $110.8 million from $195.4 million, and Humalog sales decreased to $425.2 million from $506.0 million.

Management Commentary and Outlook

The company highlighted the positive impact of its newest medicines, including Zepbound and Omvoh, which contributed $1,080.6 million and $100.9 million in sales, respectively, during the quarter. This indicates a successful introduction and rapid uptake of these new therapies. Eli Lilly's management emphasized their commitment to addressing serious health challenges through innovation and delivering life-changing medicines.